

Supplemental online content for:

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis

Douglas B. Johnson, MD, MSCI; Riyue Bao, PhD; Kristin K. Ancell, MD; Anthony B. Daniels, MD, MSc; Deborah Wallace, MSN; Jeffrey A. Sosman, MD; and Jason J. Luke, MD

J Natl Compr Canc Netw 2019;17(2):114–117

eAppendix 1: Baseline Clinical Characteristics

Appendix 1. Baseline Clinical Characteristics

Patient ID	Age, y	Sex	ECOG PS	Duration From Primary to Metastases	Prior Systemic Therapies	Liver Metastases	Number of Measurable Lesions (per RECIST)	Number of Organs Involved ^a	Size of Largest Lesion (cm)	Baseline LDH	Baseline AST	Baseline ALT	Baseline ALP	Baseline Bilirubin	Mutation Status (GNAO1/1)	PRAME Status	SF3B1 Mutation Status	Response
01-001	80	Female	1	18.3 mo	None	Yes	2	2	2.5	331 ^b	26	11	93	0.4	Unknown	Unknown	Unknown	Progressive disease
01-002	66	Male	0	5.9 mo	None	Yes	2	1	1.1	164	34	52 ^b	119	0.5	Unknown	Unknown	Unknown	Stable disease
02-001	63	Male	0	24.5 mo	Sunitinib	No	4	5	3.3	132	18	17	52	0.6	Mutant	Unknown	Wild-type	Complete response
02-002	62	Male	0	29 y	Cabozantinib	No	2	2	5.5	208	35	56 ^b	62	0.4	Mutant	Unknown	Wild-type	Stable disease
02-003	34	Male	1	36 mo	None	Yes	4	5	23.6	Unknown	52 ^b	18	503 ^b	0.9	Unknown	Unknown	Unknown	Progressive disease

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; PS, performance status. Normal range at Vanderbilt University Medical Center (patients 01-001 and 01-002)

Normal range at University of Chicago (patients 02-001–02-003)

^aIncludes nonmeasurable lesions.

^bOutside normal range for all laboratory values.